Sales Highlights (unaudited): Global Immuron exceeds AUD$5 million in sales in a fiscal year - highest sales in history March 2025 Quarter AUD$1.3 million up 2% on prior year March 2025 Year to Date AUD$5.3 million up 46% on prior year Australia March 2025 Quarter AUD$0.8 million down 8% on prior year March 2025 Year to Date... Read More

MELBOURNE, Australia, March 05, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce it has entered into an exclusive distribution agreement for the territories of Australia and New Zealand. Immuron will launch ProIBS®... Read More

MIAMI, Feb. 18, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 79 th Emerging Growth Conference on February 18 & 19, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.... Read More

Sales Highlights: Global December 2024 Quarter AUD$2.5 million up 70% on prior quarter, up 249% on pcp December 2024 Half Year AUD$4.0 million up 70% on pcp Australia December 2024 Quarter AUD$1.9 million up 83% on prior quarter, up 314% on pcp December 2024 Half Year AUD$2.9 million up 54% on pcp North America December 2024... Read More

Highlights: New Research Collaboration w ith Monash University One proposal will target Antimicrobial Resistant Pathways to develop broad spectrum therapeutic drug products Second project proposal will focus on the Develop of new therapeutic drug candidates against Vancomycin-resistant enterococci (VRE) MELBOURNE, Australia, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and... Read More

Highlights: Travelan ® (IMM-124E) Phase 2 Clinical Study Report submitted to the FDA Travelan ® (IMM-124E) Phase 2 Clinical Study Statistically Significant Immunology Results Travelan ® (IMM-124E) Phase 2 Clinical Study Statistically Significant Microbiome Responses Travelan ® P2TD (n=866) Uniformed Services University field study randomized 776 subjects MELBOURNE, Australia, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Immuron Limited... Read More

MELBOURNE, Australia, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at the Small Cap Growth Virtual Investor Conference hosted by VirtualInvestorConferences.com on Thursday 5 th December 2024 (2.30pm U.S. Eastern time). Immuron invites individual and institutional investors, as well as advisors and analysts, to... Read More

MELBOURNE, Australia, Nov. 21, 2024 (GLOBE NEWSWIRE) - - Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore presented early this morning at the 21 st Virtual Investor Summit Microcap Event (November 21, US Eastern Time). A copy of the presentation is available on the Company’s website. https://www.immuron.com.au/corporate-presentations/ This release has been authorised... Read More

MELBOURNE, AUSTRALIA / ACCESSWIRE / November 18, 2024 / Immuron Limited (NASDAQ:IMRN) has one commercial product and two pipeline assets in three clinical programs for the treatment of gut mediated diseases. The company will be available for 1-on-1 meetings throughout the day in addition to their presentation. Event: Q4 Investor Summit Presentation Time: 10:30am - 11:00am ET Location:... Read More

MELBOURNE, Australia, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be participating in a fireside chat at the Maxim Virtual Healthcare Conference on Wednesday, 16th October 2024 (4.30pm U.S. Eastern time). A copy of the presentation covering information being discussed is available on the Company’s website.... Read More

Sales Highlights: Global • September 2024 Quarter AUD$1.5 million up 13% on prior quarter Australia • September 2024 Quarter AUD$1.0 million up 3% on prior quarter North America • September 2024 Quarter AUD$0.5 million up 48% on prior quarter MELBOURNE, Australia, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC;... Read More

MELBOURNE, Australia, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), is an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases. Following discussion with the US Naval Medical Research Command (NMRC), today the Company can announce that the NMRC has completed the... Read More

Key Points Immuron completes pre-IND meeting with FDA on the development of IMM-529 as product to specifically prevent or treat Clostridioides difficile infection (CDI) Previous clinical trial data on IMM-529 provides support for continued development of IMM-529 Investigational new drug (IND) application for IMM-529 planned... Read More

Highlights: $3.5 (USD $2.3) million funding for NMRC and WRAIR approved by the U.S. Department of Defense to advance the development of Travelan. MELBOURNE, Australia, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce the funding of a new research agreement for the Naval Medical Research Command (NMRC), and... Read More

MELBOURNE, Australia, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that our Chief Executive Officer, Steven Lydeamore has been invited to present at the Emerging Growth Conference on August 22 nd , 2024. Immuron Limited invites individual and institutional investors as well as advisors and analysts, to... Read More

MELBOURNE, Australia, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to invite shareholders to attend an investor webinar on MarketOpen Direct Connect to be held on: Thursday 8 th August 2024, 11:00am Australian Eastern Standard Time (9:00am AWST). Chief Executive Officer, Steven Lydeamore will provide an update on additional data analysis of IMM-124E (Travelan ® ) Phase 2 trial and... Read More

Sales Highlights: Global • FY 2024 AUD$4.9 million up 174% on prior comparative period (pcp) • June 2024 Quarter AUD$1.3 million up 253% on pcp and 6% on prior quarter Australia • FY 2024 AUD$3.7 million up 223% on pcp • June 2024 Quarter AUD$1.0 million up 200% on pcp and 11% on prior quarter USA • FY 2024 Record sales of AUD$1.1 million up 74% on pcp • June 2024 Quarter AUD$0.3 million up 546% on pcp; down 1% on prior... Read More

MELBOURNE, Australia, July 02, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce that it has filed a pre-IND (investigational new drug) application with the United States Food and Drug Administration (FDA) for... Read More

MELBOURNE, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that our Chief Executive Officer, Steven Lydeamore has been invited to present at the Emerging Growth Conference on June 13 th , 2024. Immuron Limited invites individual and institutional investors as well as advisors and analysts, to... Read More

MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to advise our Chief Executive Officer Steven Lydeamore will be presenting at Peak Asset Management’s Peak Sky High luncheon in Melbourne on June 1, 2024. A copy of the presentation slide deck is available on the Company’s website.... Read More

MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Dr Roger Aston has resigned from his position as Non-Executive Director effective today. Roger was appointed as a Director in 2012 and served as Non-Executive Chairman from 2012 to 2023. Immuron over the past few years has been ongoing with... Read More

MELBOURNE, Australia, May 07, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference, on Wednesday 8th May. The next Emerging Growth Conference will be presented on... Read More

MELBOURNE, Australia, May 03, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, advises that Stephen Anastasiou has resigned from his position as Non-Executive Director effective today to focus on his other business interests. Stephen has served as a Director since 2013 and has provided valued contributions and experienced counsel to the... Read More

MELBOURNE, Australia, April 15, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore together with our Chief Scientific Officer, Dr. Jerry Kanellos and Research & Development Manager, Dr. Joanne Casey will be hosting a Live Virtual Event on Tuesday, April 30 at 10am AEST /... Read More

Sales Highlights: Global FYTD Mar 2024 AUD$3.6 million up 154% on (prior comparative period) pcp Mar 2024 Quarter AUD$1.3 million up 51% on pcp and 75% on last quarter Australia FYTD Mar 2024 AUD$2.8 million up 234% on pcp Mar 2024 Quarter AUD$0.9 million up 66% on pcp and 99% on last quarter USA FYTD Mar 2024 AUD$0.8 million up 35% on pcp Mar 2024 Quarter AUD$0.3 million up 7% on pcp and 18% on last quarter Sales commenced... Read More

Highlights: Immuron proceeding to Phase 3 registration strategy with the FDA Travelan® topline clinical trial results demonstrate protective efficacy with single daily dose 36.4% protective efficacy against Enterotoxigenic Escherichia coli (ETEC) induced moderate to severe diarrhea was observed in the Travelan® group compared to the placebo group (primary endpoint) 66.7% protective efficacy against ETEC induced severe... Read More

MELBOURNE, Australia, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Research & Development Manager, Joanne Casey, PhD will be presenting at the Australian Biologics Festival 2024 on Wednesday, 21 st February in Melbourne, Australia. A copy of the presentation slide deck is available on the Company’s... Read More

Highlights: Travelan ® sales YTD Jan 2024 of $2.7 million exceed peak full year FY20 sales of $2.5 million Australian Travelan ® YTD Jan 2024 sales $2.1 million USA Travelan ® YTD Jan 2024 sales $0.6 million Canadian sales recommenced through McKesson MELBOURNE, Australia, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is... Read More

MELBOURNE, Australia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at the Monsoon Communications Investor function on Thursday, 8 th February in Sydney, Australia. A copy of the presentation slide deck is available on the Company’s website.... Read More

Highlights: Record half yearly Travelan ® sales of $2,334,969 Total sales of A$2,355,580 in H1, FY24 $1,771,932 increase on H1, FY23 sales 51% higher than pre-pandemic period H1, FY20 sales MELBOURNE, Australia, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record half yearly sales (unaudited net sales)... Read More

Highlights: US Naval Medical Research Command (NMRC) campylobacter clinical program completes in-patient phase Manufacture of IMM-529 drug substance to support the Pre-IND information package has been completed Pre-IND submission to the U.S. Food and Drug administration (FDA) planned for H1 2024 Travelan ® clinical study inpatient phase completed and 6 month follow up visits planned MELBOURNE, Australia, Dec. 22, 2023 (GLOBE... Read More

Highlights: First participants enrolled in the US Naval Medical Research Command Clinical Trial Clinical Study initiated to evaluate the efficacy of a new Immuron clinical product to protecting volunteers against moderate to severe campylobacteriosis New CampETEC product is a prophylactic therapeutic designed to protect against Campylobacter and Enterotoxigenic Escherichia coli (ETEC) infections, two of the major causes of... Read More

MELBOURNE, Australia, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to invite shareholders to attend an investor webinar on The Watchlist, to be held on Tuesday, 14th November, 2023, 1:00pm AEDT/10:00am AWST. CEO Steven Lydeamore will provide an overview and update on the business and upcoming milestones. Following... Read More

MELBOURNE, Australia, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to advise our Chief Executive Officer, Steven Lydeamore, presented at AusBioInvest 2023 on Monday, October 30th in the 9.40am – 10.35am session (AEST) at the Park Hyatt, Melbourne, Australia. A copy of the presentation being made at AusBioInvest... Read More

Highlights: Second cohort of 34 healthy volunteers enrolled in the Travelan ® Clinical Trial Clinical Trial to examine a dosing regimen for Travelan ® more suited to the US military has commenced the second cohort The clinical study 6 month follow up of Cohorts 1 and 2 anticipated to be completed in April 2024 Travelan ® is known to protect against the onset of Traveler’s diarrhea (TD), the most common illness reported by... Read More

Highlights: Record quarterly Travelan ® sales of $1,550,240 Total sales of A$1,565,767 in Q1, FY24 $1,508,933 increase on Q1, FY23 sales 130% higher than pre-pandemic period Q1, FY20 sales MELBOURNE, Australia, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record quarterly sales (unaudited net sales) of... Read More

Highlights: Record monthly Travelan ® sales Australian sales of A$1.18 M in August 2023 (7984% increase on August 2022 sales) MELBOURNE, Australia, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record monthly sales (unaudited net sales) of its over-the-counter gastrointestinal and digestive health... Read More

MELBOURNE, Australia, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting virtually at the H.C. Wainwright 25 th Annual Global Investment Conference on September 11 th . The webcast to this presentation will be available here at 7am Eastern... Read More

MELBOURNE, Australia, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that it will be presenting at The Military Health System Research Symposium (MHSRS), in Kissimmee, Florida from the 14 th to the 17 th of August 2023. The MHSRS is the U.S. Department of Defense’s premier scientific meeting that focuses... Read More

Highlights: First cohort of 30 healthy volunteers enrolled in the Travelan ® Clinical Trial Clinical Trial to examine a dosing regimen for Travelan ® more suited to the US military has commenced Final 30 participants anticipated to be enrolled and commence the study in October 2023 Travelan ® is known to protect against the onset of Travelers diarrhea (TD), the most common illness reported by travelers MELBOURNE, Australia,... Read More

MELBOURNE, Australia, July 24, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at the 17th Bioshares Biotech Summit in Hobart, Australia on July 24 th . A copy of the presentation slide deck is available on the Company’s website.... Read More

Highlights: Ateria has launched Juvia™ containing breakthrough natural ingredient ERME™ in Australia New clinical study is underway with the NHS in Swansea, Wales in people diagnosed with IBS due to malfermentation of carbohydrates in the gut. MELBOURNE, Australia, July 11, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has... Read More

Highlights: Australian FY23 sales of A$1.16 M (478% increase on FY22 sales) USA FY23 Travelan® sales of A$643 k (28% increase on FY22 sales) Global FY23 sales of A$1.80 M (136% increase on FY22 sales) MELBOURNE, Australia, July 05, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce FY23 sales (unaudited net sales)... Read More

MELBOURNE, Australia, June 30, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce the transition of Paul Brennan from Non-Executive Director to Chairman, effective July 1, 2023. Dr Roger Aston will continue on the Board, transitioning from Chairman to Non-Executive Director. The Board determined that, having... Read More

Highlights: Immuron Board approves IMM-529 cGMP manufacturing and to proceed with FDA pre-IND submission Recruitment and screening update for Travelan® Controlled Human Infection Model (CHIM) Clinical Trial MELBOURNE, Australia, June 22, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral... Read More

Highlights: Immuron receives approval from U.S. Army Medical Research and Development Command Recruitment and screening of healthy volunteers for Travelan® Controlled Human Infection Model (CHIM) Clinical Trial is in progress Clinical Trial to examine a dosing regimen for Travelan® more suited to the US military will commence shortly Travelan® is known to protect against the onset of Travelers diarrhea (TD), the most common... Read More

Highlights: U.S. Food and Drug administration (FDA) remove clinical hold on New Campylobacter ETEC Therapeutic IND application US Naval Medical Research Centre (NMRC) satisfactorily addressed all clinical hold issues identified by the FDA IND to evaluate the efficacy of new Campylobacter ETEC Therapeutic in two human Phase 2 clinical trials is now active One trial will focus on the ability of the hyperimmune product to... Read More

MELBOURNE, Australia, May 02, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to provide a copy of the presentation being made today in Melbourne at Coffee Microcaps Conference by our Chief Executive... Read More

MELBOURNE, Australia, April 19, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to provide the Q3 FY23 Investor Presentation for the business update webinar to be held today at 11:00 am (AEST) . The... Read More

MELBOURNE, Australia, April 11, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to advise it will provide a business update for the quarter ended 31 March 2023 (Q3 FY23). Investors are invited to join a... Read More

Highlights: Australian Q3 FY23 sales of A$577 k (201% of 1H sales) North American Q3 FY23 Travelan ® sales of A$298 k (100% of 1H sales) Global Q3 YTD FY23 sales of A$1.46 M represent an increase of 239% compared with the corresponding period in FY22 of A$430 k MELBOURNE, Australia, April 06, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical... Read More

MELBOURNE, Australia, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, invites investors to join a live webcast hosted by Steven Lydeamore, CEO of Immuron Limited. Tuesday, 28 February 2023 at 11:00am... Read More

MELBOURNE, Australia, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, today announces that a response letter has been submitted to the US Food and Drug Administration (FDA). Immuron has previously reported... Read More

Highlights: First participants enrolled in USU Travelan Clinical Trial Field Study 157 participants successfully randomized into the Clinical Study Plans in place to enrol in 1302 healthy volunteers in total Infectious diarrhea is the most common illness reported by travelers & military personnel MELBOURNE, Australia, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally... Read More

MELBOURNE, Australia, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to announce that has been granted a European Patent for compositions and methods for the treatment and/or prophylaxis of... Read More

Highlights: Immuron receives U.S. Food and Drug administration (FDA) approval for Travelan Investigational New Drug (IND) application IND to evaluate the efficacy of a single dose of Travelan to prevent infectious diarrhea caused by ETEC is now active Plans in place to initiate a Human clinical trial in 60 healthy volunteers in the USA Clinical Trial to examine a dosing regimen for Travelan more suited for use by the US... Read More

Highlights: Investigational New Drug (IND) application submitted to the U.S. Food and Drug administration (FDA) Plans in place to initiate a Human clinical trial in 60 healthy volunteers in the USA Clinical Trial to examine a dosing regimen for Travelan more suited for use by the US military Infectious diarrhea is the most common illness reported by travelers MELBOURNE, Australia, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Immuron... Read More